Indication	Discovery	Optimization	Lead Compound	IND
Oncology
PARP Inhibitor Program    • Breast Cancer BRCA- • Ovarian Cancer BRCA- • Combination				Mid-2010
Cyp17 Inhibitor Program    • Prostate Cancer
Infectious Disease
Glycopeptide Program    • MRSA • Resistant Infections				Mid-2010

PARP Inhibitor Program
Next generation poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of solid tumors that combine favorable properties including high potency, single agent and combination activity, superior PK and high oral bioavailability. Potential to be “best in class”. Currently in pre-clinical development and will be in a position to select a “lead” compound by mid-2009 and to begin clinical trials by mid-2010.

Click here to learn more about PARP Inhibitors

Cyp17 Inhibitor Program
Next generation Cyp17 inhibitors for the treatment of castration resistant prostate cancer with potent pre-clinical activity and superior PK and solubility. Cyp17 is a key enzyme in the generation of androgens.

Glycopeptide Program
Next generation glycopeptides with activity against MRSA and PK properties superior to vancomycin. Currently in pre-clinical development and will be in a position to select a “lead” candidate by mid-2009 and begin clinical trials by mid-2010.